EPAS1 and nonpapillary renal cell carcinoma: Additionally, PT 2385, PT 2399, TSL‐1, Belzutifan and Casdatifan are potent and selective small‐molecule inhibitors of HIF‐2α, which can effectively treat ccRCC.